Trial Profile
A phase III trial comparing subcutaneous and intravenous tocilizumab in patients with rheumatoid arthritis in Japan.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 May 2016
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary) ; Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms MUSASHI
- Sponsors Chugai Pharmaceutical
- 27 Aug 2013 Results published in the Arthritis care and research.
- 14 Nov 2012 12-week outcomes of the extension study presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 09 Jun 2012 Results presented at the 13th Annual Congress of the European League Against Rheumatism.